17-Hydroxy Progesterone (OHP) at Test Zone Diagnostic Center

Understanding the 17-Hydroxy Progesterone (OHP) Test

The 17-Hydroxy Progesterone (OHP) test is a highly specialized endocrine investigation used to measure the levels of 17-hydroxyprogesterone, a natural steroid hormone produced by the adrenal glands and the gonads. This hormone serves as a critical intermediate building block in the complex biochemical pathway of steroidogenesis, which ultimately produces cortisol, the body’s primary stress hormone. The synthesis of cortisol from cholesterol involves a series of enzymatic steps. 17-OHP is converted into 11-deoxycortisol by the action of the enzyme 21-hydroxylase, which is subsequently converted into active cortisol. When there is an inherited genetic mutation leading to a deficiency of the 21-hydroxylase enzyme, this metabolic pathway is blocked. Consequently, 17-OHP cannot be converted, leading to its massive accumulation in the bloodstream. This biological phenomenon is the primary diagnostic indicator for Congenital Adrenal Hyperplasia (CAH), a group of autosomal recessive disorders affecting adrenal steroid synthesis.

At Test Zone Diagnostic Center in Lahore, Pakistan, the 17-Hydroxy Progesterone (OHP) test is performed using state-of-the-art laboratory technology, including advanced Chemiluminescent Immunoassays (CLIA) and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). These cutting-edge analytical methodologies ensure the highest level of diagnostic sensitivity and specificity, which is crucial for detecting even minute fluctuations in hormone levels. Evaluating 17-OHP levels is of paramount clinical importance not only for newborn screening but also for investigating reproductive disorders, menstrual irregularities, hirsutism, and adrenal tumors in adults. By providing precise quantitative measurements, this test enables endocrinologists, pediatricians, and gynecologists to formulate accurate, evidence-based treatment plans for patients presenting with complex hormonal imbalances.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of your 17-Hydroxy Progesterone (OHP) test results at Test Zone Diagnostic Center, patients must strictly adhere to the following preparation guidelines:

• Diurnal Variation Considerations: 17-OHP levels follow a strict circadian rhythm, peaking in the early morning hours. Therefore, blood sample collection must be scheduled between 7:00 AM and 9:00 AM.
• Menstrual Cycle Timing: For menstruating females, the test should ideally be performed during the early follicular phase (typically days 3 to 5 of the menstrual cycle) to avoid false elevations naturally occurring during the luteal phase.
• Fasting Requirements: While a strict fast is not always mandatory, an overnight fast of 8 to 12 hours is highly recommended to prevent lipemia in the blood sample, which can interfere with optical assay systems.
• Medication Disclosure: Patients must inform their healthcare provider and the laboratory staff of all medications they are currently taking, particularly glucocorticoids (such as hydrocortisone, prednisone, or dexamethasone), oral contraceptives, or progesterone therapies, as these can suppress or alter endogenous hormone levels.
• Stress Reduction: Physical and emotional stress can stimulate the hypothalamic-pituitary-adrenal (HPA) axis, leading to transiently elevated hormone levels. Patients are advised to rest quietly for 15 minutes before the blood draw.

During the Procedure

The blood collection process at Test Zone Diagnostic Center is designed to be quick, safe, and comfortable. Upon arrival at our modern facility in Lahore, Pakistan, you will be guided to a dedicated phlebotomy station. The clinical procedure involves the following steps:

• Patient Identification: The phlebotomist will verify your identity using at least two unique identifiers (e.g., full name and registration number) to ensure absolute sample traceability.
• Site Selection and Cleansing: You will be seated comfortably, and the phlebotomist will inspect your arm to locate a suitable vein, typically the median cubital vein in the antecubital fossa. The skin is thoroughly disinfected using a 70% isopropyl alcohol swab in a circular motion and allowed to air dry.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection system is gently inserted into the vein. A serum separator tube (SST, gold-top) or a plain red-top tube is filled with the required volume of blood (approximately 3 to 5 mL).
• Post-Collection Care: Once the sample is collected, the needle is withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad to prevent hematoma formation. A small adhesive bandage is then applied.
• Sample Processing: The blood sample is allowed to clot naturally at room temperature for 30 minutes. It is then centrifuged at 3000 RPM for 10 minutes to separate the serum. The isolated serum is immediately transferred to the analytical department for high-precision testing.

When is a 17-Hydroxy Progesterone (OHP) Performed?

Screening for Congenital Adrenal Hyperplasia (CAH) in Newborns

The primary and most critical clinical indication for the 17-Hydroxy Progesterone (OHP) test is screening newborns for classic Congenital Adrenal Hyperplasia (CAH). Infants born with the severe “salt-wasting” form of CAH lack both cortisol and aldosterone, leading to a life-threatening adrenal crisis within the first few weeks of life, characterized by severe dehydration, hyponatremia, hyperkalemia, and cardiovascular collapse. Female newborns often present with ambiguous genitalia due to prenatal exposure to high adrenal androgen levels. Performing the 17-OHP test shortly after birth allows for rapid diagnosis and immediate initiation of life-saving hormone replacement therapy, preventing catastrophic clinical outcomes.

Investigating Hirsutism and Virilization in Females

Physicians frequently order a 17-OHP test for adolescent girls and adult women presenting with signs of androgen excess, such as hirsutism (excessive male-pattern hair growth on the face, chest, and back), severe cystic acne, male-pattern baldness, and virilization (deepening of the voice or clitoromegaly). These symptoms indicate elevated levels of circulating male hormones. The 17-OHP test helps clinicians differentiate between common ovarian conditions like Polycystic Ovary Syndrome (PCOS) and less common but clinically distinct adrenal conditions, such as non-classic (late-onset) Congenital Adrenal Hyperplasia (NCCAH), which requires a completely different therapeutic approach.

Evaluating Irregular Menstruation and Female Infertility

Chronic anovulation, irregular menstrual cycles (oligomenorrhea), or the complete absence of menstruation (amenorrhea) are common clinical challenges in reproductive medicine. When these symptoms are accompanied by difficulties in conceiving, a comprehensive endocrine workup is warranted. Because mild, late-onset adrenal enzyme deficiencies can disrupt the delicate hypothalamic-pituitary-ovarian axis and impair normal ovulation, measuring 17-OHP is an essential step in identifying the root endocrine cause of infertility, allowing for targeted therapies that restore ovulatory function and improve fertility outcomes.

Monitoring Therapeutic Efficacy in Diagnosed CAH Patients

For individuals already diagnosed with Congenital Adrenal Hyperplasia, the 17-Hydroxy Progesterone (OHP) test is an indispensable tool for long-term clinical monitoring. Patients with CAH require lifelong glucocorticoid replacement therapy to substitute for deficient cortisol and suppress the pituitary gland’s overproduction of ACTH. Regular monitoring of 17-OHP levels helps endocrinologists assess whether the medication dosage is optimal. Maintaining 17-OHP within a specific target range ensures that adrenal androgen production is adequately suppressed without causing the adverse effects of glucocorticoid over-treatment, such as growth retardation in children or metabolic syndrome in adults.

Assessing Late-Onset (Non-Classic) Adrenal Hyperplasia in Adults

Non-classic Congenital Adrenal Hyperplasia (NCCAH) is a milder, non-life-threatening form of 21-hydroxylase deficiency that may not present symptoms until late childhood, adolescence, or even adulthood. Patients with NCCAH have partial enzyme activity and do not experience neonatal salt-wasting or ambiguous genitalia. Instead, they present later in life with premature pubarche, accelerated bone age, short stature, or reproductive issues. The 17-OHP test, often performed as part of an ACTH stimulation test, is the gold standard for identifying this late-onset genetic variation, enabling precise medical management and genetic counseling.

What Does a 17-Hydroxy Progesterone (OHP) Detect?

The 17-Hydroxy Progesterone (OHP) test is highly sensitive and capable of detecting a wide spectrum of biochemical states, genetic mutations, and physiological conditions. Specifically, this diagnostic investigation detects:

• Classic 21-Hydroxylase Deficiency (Salt-Wasting Form): Characterized by extremely high levels of 17-OHP, indicating a complete or near-complete lack of the 21-hydroxylase enzyme.
• Classic 21-Hydroxylase Deficiency (Simple Virilizing Form): Identified by significantly elevated 17-OHP levels in infants who present with virilization but do not exhibit severe renal salt-wasting.
• Non-Classic (Late-Onset) Congenital Adrenal Hyperplasia: Detected via moderately elevated baseline morning 17-OHP levels or markedly exaggerated responses during an ACTH stimulation test.
• Heterozygote Carrier Status: Individuals carrying a single mutated allele for 21-hydroxylase deficiency may show mild, borderline elevations in 17-OHP under physiological stress.
• Adrenal Cortical Tumors: Certain benign adenomas or malignant adrenal cortical carcinomas can autonomously secrete steroid intermediates, including 17-OHP.
• Ovarian Hyperthecosis: A severe form of follicular luteinization in the ovaries that can lead to elevated levels of progesterone and its intermediates.
• Polycystic Ovary Syndrome (PCOS) Associations: Helps rule out adrenal contributions to hyperandrogenism in patients presenting with classic PCOS symptoms.
• 11-Beta-Hydroxylase Deficiency: While characterized primarily by elevations in 11-deoxycortisol, cross-reactivity and pathway backup can cause secondary mild elevations in 17-OHP.
• 3-Beta-Hydroxysteroid Dehydrogenase Deficiency: A rare form of CAH that can alter the ratio of various steroid intermediates, including 17-OHP.
• Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysregulation: Reflects abnormal signaling between the pituitary gland and the adrenal cortex.
• Physiological Luteal Phase Elevations: Normal, non-pathological increases in 17-OHP produced by the corpus luteum during the second half of the menstrual cycle.
• Pregnancy-Induced Steroid Alterations: Normal physiological elevations in maternal 17-OHP levels due to placental synthesis and fetal adrenal activity.
• Exogenous Corticosteroid Suppression: Artificially low levels of 17-OHP resulting from the therapeutic use of synthetic glucocorticoids.
• Premature Adrenarche: Early activation of the adrenal glands in young children, leading to mild elevations in adrenal androgens and 17-OHP.
• Idiopathic Hirsutism: Helps confirm normal adrenal function in women with excess hair growth but no biochemical androgen abnormalities.
• Enzyme Kinetics Abnormalities: Identifies subtle defects in the multi-step steroid hormone synthesis pathway.
• Cortisol Synthesis Blockages: Pinpoints the exact metabolic block responsible for glucocorticoid deficiency.
• Secondary Hyperandrogenism: Evaluates the adrenal contribution to overall systemic androgen excess.
• ACTH Stimulation Responsiveness: Measures the functional reserve and enzymatic capacity of the adrenal cortex under synthetic hormone stimulation.
• Normal Adrenal Function: Rules out congenital and acquired adrenal enzyme deficiencies, providing clinical reassurance.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for diagnostic test results can be a source of anxiety for patients and their families. Therefore, we utilize fully automated immunoassay analyzers and high-precision chromatography systems to ensure both rapid processing and absolute accuracy. For routine 17-Hydroxy Progesterone (OHP) tests, the standard turnaround time is typically 24 to 48 hours from the time of sample collection. If specialized Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is required for confirmatory testing, the processing time may extend to 3 to 5 business days due to the highly complex extraction and calibration protocols involved.

Once your report is finalized and verified by our consultant pathologist, you will receive an immediate SMS notification on your registered mobile number. Patients can securely access, view, and download their digital reports through the Test Zone online portal from the comfort of their homes. Physical copies of the reports can also be collected directly from our main reception desk at our conveniently located center in Lahore, Pakistan. We maintain a comprehensive digital archive of all patient records, allowing for easy retrieval and comparison of historical lab results during follow-up consultations.

17-Hydroxy Progesterone (OHP) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Newborns (0 – 3 Days)	< 630 ng/dL (varies significantly by birth weight and gestational age)	> 2,000 ng/dL (highly suggestive of classic Congenital Adrenal Hyperplasia)
Pre-pubertal Children	3 – 90 ng/dL	Elevated in premature adrenarche, early puberty, or mild CAH variants
Adult Males	27 – 220 ng/dL	Elevated in adrenal tumors, late-onset CAH, or testicular source alterations
Adult Females (Follicular Phase)	15 – 70 ng/dL	> 200 ng/dL (suggestive of non-classic CAH, PCOS, or adrenal hyperplasia)
Adult Females (Luteal Phase)	35 – 290 ng/dL	Markedly elevated levels exceeding 500 ng/dL, requiring clinical correlation
Postmenopausal Females	< 51 ng/dL	Elevated in functional adrenal neoplasms or late-onset enzyme deficiencies
ACTH Stimulation Test (Post-Stim)	< 300 ng/dL	> 1,000 ng/dL (diagnostic threshold for non-classic 21-hydroxylase deficiency)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for 17-Hydroxy Progesterone (OHP)?

• Experienced Healthcare Professionals: Our laboratory is led by highly qualified consultant pathologists and clinical biochemists who oversee all testing procedures.
• Patient-Focused Care: We prioritize patient comfort, privacy, and dignity throughout the entire diagnostic journey.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to international standards of laboratory medicine, ensuring precise and reproducible results.
• Professional Reporting: Our reports are comprehensive, easy to read, and include clear, age- and gender-specific reference ranges.
• Modern Diagnostic Approach: We utilize state-of-the-art automated immunoassay platforms and advanced molecular diagnostics.
• Comfortable Environment: Our sample collection areas are designed to be clean, hygienic, and stress-free for patients of all ages, including infants.
• Convenient Location: Located centrally in Lahore, Pakistan, our diagnostic center is easily accessible to patients from all parts of the city.
• Commitment to Accurate Diagnosis: We participate in rigorous external quality assurance programs to maintain the highest level of diagnostic accuracy.